Alhavi Discloses Approved Average Price Rise for a Group of Medicines

Alhavi, traded as DHVP, said in a group-A Codal disclosure published on Monday, October 26, 2026, that Iran's Food and Drug Administration had authorised a 49% average increase in the selling prices of 13 of its medicines. The form dates both approval and implementation to August 23, 2026; publication in October does not mean the prices first took effect today.

The company cites higher raw-material costs. The filing does not give the old and new prices of each product and puts this product group's share of last year's revenue at 2%, so its eventual effect on company profit cannot be calculated from the notice alone.